Bipolar Disorder Clinical Research Study 2019
I am very excited to announce the Bipolar Disorder Clinical Research Study my Clinic, 3rd Eye Hypnotherapy Clinic, in Calgary, Alberta, in co-ordination with The Association of Registered Clinical Hypnotherapists (ARCH), will be conducting this year with patients diagnosed with Bipolar l Disorder and Bipolar ll Disorder. This is a new integrated approach that combines the therapeutic techniques of Counselling, Cognitive Behavioral Therapy, and Hypnotherapy to provide patients with Bipolar Disorder a new 3 months free treatment option in preventing and reducing the frequency and level of severity of manic, hypomanic, and depressive episodes, in addition to increasing the time frame and duration of the maintenance phase.
This is a new integrated approach that combines the therapeutic techniques of Counselling, Cognitive Behavioral Therapy, and Hypnotherapy to provide patients with Bipolar Disorder a new 3 month treatment option in preventing and reducing the frequency and level of severity of manic, hypomanic, and depressive episodes, in addition to increasing the time frame and duration of the maintenance phase.
In the extensive research I have conducted, particularly studying the case studies and work of Dr. David J. Miklowitz and Dr. Ronald R. Fieve, true pioneers in their field; I have, in addition to many other Clinicians during their work with Bipolar Disorder patients, identified a common thread within most patients: a trigger that usually seems to precipitate a manic, hypomanic, or depressive episode.
Environmental stress has been evidenced to play a dominant role in manic, hypomanic, and depressive episodes. Therefore, this treatment protocol that I have created is focused on, and targets the environmental stress component linked to causation within this Clinical Study; reducing each patients stress levels, identifying and desensitizing each patient’s individual triggers, which may then result in the time frame between episodes increasing (maintenance phase), and the level of severity during each episode actually decreasing, in addition to the added benefit of reducing stress levels, anxiety, general discomfort, and insomnia during the maintenance phase.
Patients are expected to continue administering their prescribed medications throughout and following treatment, and continue to be monitored by their treating Psychiatrist during and after this treatment protocol.
The study results will be published in book form in early 2020.